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Abstract
Background: The research emphasis in anti-cancer drug discovery has always been to search for a drug with the
greatest antitumor potential but fewest side effects. This can only be achieved if the drug used is against a specific
target located in the tumor cells. In this study, we evaluated Minichromosome Maintenance Protein 7 (MCM7) as a
novel therapeutic target in cancer.
Results: Immunohistochemical analysis showed that MCM7 was positively stained in 196 of 331 non-small cell
lung cancer (NSCLC), 21 of 29 bladder tumor and 25 of 70 liver tumor cases whereas no significant staining was
observed in various normal tissues. We also found an elevated expression of MCM7 to be associated with poor
prognosis for patients with NSCLC (P = 0.0055). qRT-PCR revealed a higher expression of MCM7 in clinical bladder
cancer tissues than in corresponding non-neoplastic tissues (P < 0.0001), and we confirmed that a wide range of
cancers also overexpressed MCM7 by cDNA microarray analysis. Suppression of MCM7 using specific siRNAs
inhibited incorporation of BrdU in lung and bladder cancer cells overexpressing MCM7, and suppressed the growth
of those cells more efficiently than that of normal cell strains expressing lower levels of MCM7.
Conclusions: Since MCM7 expression was generally low in a number of normal tissues we examined, MCM7 has
the characteristics of an ideal candidate for molecular targeted cancer therapy in various tumors and also as a
good prognostic biomarker for NSCLC patients.
Background
The emergence of effective cancer chemotherapy is one
of the major medical advances of late years [1]. Adju-
vant chemotherapy for lung, breast or colon cancer can
augment the survival benefit afforded by surgical man-
agement [2-4]. Even in patients with advanced solid
tumors or recurrences following surgery, chemotherapy
can offer lengthened survival of worthwhile quality. In
those patients, however, the therapeutic index is narrow:
responses are usually partial, often disappointingly brief
and unpredictable [5]. In addition, many antitumor
agents have also been troubled with issues of sometimes
unexpected side effects. These circumstances accentuate
the limitation of cytotoxic chemotherapy. Therefore, it
remains essential to discover novel therapeutic targets
to extend the capability of cancer chemotherapy.
DNA replication in eukaryotic cells is a highly regu-
lated process that ensures the accurate duplication of
genetic information while preserving genome stability. A
large number of molecular players, including minichro-
mosome maintenance (MCM) proteins, are involved in
DNA replication [6-8]. MCM proteins are essential
replication initiation and elongation factors originally
found in Saccharomyces cerevisiae,e x i s t i n gi na
* Correspondence: ryuji@ims.u-tokyo.ac.jp
1Laboratory of Molecular Medicine, Human Genome Center, Institute of
Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan
Full list of author information is available at the end of the article
Toyokawa et al. Molecular Cancer 2011, 10:65
http://www.molecular-cancer.com/content/10/1/65
© 2011 Toyokawa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.functional complex consisting of MCM2-7. They are
evolutionarily conserved in all eukaryotes [9]. The MCM
complex belongs to the AAA+ (ATPases associated with
various cellular activities) family, and ensures that DNA
undergoes a single round of replication per cell cycle by
a licensing mechanism [9-13]. The MCM4, 6 and 7 sub-
complex possesses DNA helicase activity that promotes
unwinding of double stranded DNA at the replication
forks [14-16]. Although it is known that aberrant DNA
replication leads to pathological disorders including can-
cer, how dysregulated MCM proteins contribute to car-
cinogenesis, and aggressive cancer with poor prognosis,
is unclear.
In this study, we demonstrate that dysregulation of
MCM7 expression is observed in various types of cancer
and correlates with a negative outcome in patients with
NSCLC after surgical resection. This work forms the
basis for further functional studies, which will explore
MCM7 as a potential therapeutic and prognostic target
in lung and other cancers.
Materials and methods
Cell lines and lung tissue samples
Cancer cell lines used in this study were as follows: lung
adenocarcinoma (ADC) NCI-H1781, NCI-H1373,
LC319, A549 and PC-14; lung squamous cell carcinoma
(SCC) SK-MES-1, NCI-H2170, NCI-H520, NCI-H1703
and RERF-LC-AI; lung large cell carcinoma (LCC) LX1;
small cell lung cancer (SCLC) SBC-3, SBC-5, DMS273
and DMS114; bladder cancer SW780, RT4 and 5637;
liver cancer HepG2, SNU475 and Huh7; colorectal can-
c e rS W 4 8 0 ,L o V oa n dH C T 1 1 6 .H u m a ns m a l la i r w a y
epithelial cells (SAECs), normal human lung fibroblasts
(IMR-90, WI-39 and HFL-1) and normal human colon
fibroblasts (CCD-18Co) were used as normal control
cells. All cell lines were grown in monolayers in appro-
priate media supplemented with 10% fetal bovine serum
and 1% antibiotic/antimycotic solution (Sigma). All cell
lines were maintained at 37°C in humid air with 5%
CO2 (except for SW780), or without CO2 (SW780).
Cells were transfected with FuGENE6™ (Roche Applied
Science, Penzberg, Germany) according to the manufac-
turer’s protocols. Primary non-SCLC (NSCLC) tissue
samples as well as their corresponding normal tissues
adjacent to resection margins, from patients having no
anticancer treatment before tumor resection, had been
obtained earlier with informed consent [17-19]. All
tumors were staged on the basis of the pathologic
tumor-node-metastasis classification of the International
Union Against Cancer. A total of nine frozen primary
lung cancer tissues for RNA extraction were obtained as
published earlier [18,19]. Formalin-fixed primary lung
tumors and adjacent normal lung tissue samples used
for immunostaining on tissue microarrays had been
obtained from 331 patients undergoing curative surgery
at Saitama Cancer Center (Saitama, Japan) [20,21]. To
be eligible for this study, tumor samples were selected
from patients who fulfilled all of the following criteria:
(a) patients suffered primary NSCLC with histologically
confirmed stage (only pT1 to pT4, pN0 to pN2, and
pM0); (b) patients underwent curative surgery, but did
not receive any preoperative treatment; (c) among them,
NSCLC patients with positive lymph node metastasis
(pN1-pN3) were treated with platinum-based adjuvant
chemotherapies after surgical resection, whereas patients
with pN0 did not receive adjuvant chemotherapies; and
(d) patients whose clinical follow-up data were available.
This study and the use of all clinical materials men-
tioned were approved by individual institutional ethics
committees.
Bladder tissue samples and RNA preparation
Bladder tissue samples and RNA preparation were
described previously [22-24]. Briefly, 136 surgical speci-
mens of primary urothelial carcinoma were collected,
either at cystectomy or transurethral resection of blad-
der tumor (TURBT), and snap frozen in liquid nitrogen.
Twenty-three specimens of normal bladder urothelial
tissue were collected from areas of macroscopically nor-
mal bladder urothelium in patients with no evidence of
malignancy. Approximately 10,000 cells were microdis-
sected from both stromal and epithelial/tumor compart-
ments in each tissue. RNA was extracted using an
RNeasy Micro Kit (QIAGEN, Crawley, UK). Areas of
cancer or stroma containing significant inflammatory
areas of tumor or stroma containing significant inflam-
matory cell infiltration were avoided to prevent contami-
nation [24]. Use of tissues for this study was approved
by Cambridgeshire Local Research Ethics Committee
(Ref 03/018).
Expression profiling in cancer using cDNA microarrays
We established a genome-wide cDNA microarray with
36,864 cDNAs selected from UniGene database of the
National Center for Biotechnology Information (NCBI).
This microarray system was constructed essentially as
described previously [18,25,26]. Briefly, the cDNAs were
amplified by RT-PCR using poly (A)
+ RNAs isolated
from various human organs as templates; the lengths of
the amplicons ranged from 200 to 1,100 bp, without any
repetitive or poly (A) sequences. Many types of tumor
and corresponding non-neoplastic tissues were prepared
in 8-μm, as described previously [25]. A total of 30,000
- 40,000 cancer or noncancerous cells were collected
selectively using the EZ cut system (SL Microtest
GmbH, Jena, Germany) according to the manufacturer’s
protocol. Extraction of total RNA, T7-based amplifica-
tion, and labeling of probes were performed as described
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amplified RNA (aRNA) from each cancerous and non-
cancerous tissue was then labeled, respectively, with
Cy3-dCTP or Cy5-dCTP.
Quantitative real-time PCR
As described previously, we prepared 136 bladder cancer
and 23 normal bladder tissues in Addenbrooke’s Hospi-
tal, Cambridge [27]. Specific primers for human GAPDH
(housekeeping gene) and MCM7 were designed (primer
sequences in Additional file 1). PCR reactions were per-
formed using the LightCycler
® 480 System (Roche
Applied Science) following the manufacture’s protocol.
siRNA transfection and cell growth assay
siRNA oligonucleotide duplexes were purchased from
Sigma-Aldrich (St. Louis, MO, USA) for targeting the
human MCM7 transcripts. siEGFP and siNegative con-
trol (siNC), which consists of three different oligonu-
cleotide duplexes, were used as control siRNAs. The
siRNA sequences are described in Additional file 2.
siRNA duplexes (100 nM final concentration) were
transfected into lung and bladder cancer cell lines with
Lipofectamine 2000 (Life Technologies, Carlsbad, CA,
USA) for 72 h, and cell growth was examined using the
Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) [28].
Western blot analysis
Whole cell lysates were prepared from the cells with
RIPA-like buffer, and total protein (10 μg) was trans-
ferred to nitrocellulose membrane. The membrane was
probed with anti-MCM7 antibody (141.2, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). ACTB (I-19,
Santa Cruz Biotechnology) was used to ensure equal
loading and transfer of proteins. Protein bands were
detected by incubating with horseradish peroxidase-con-
jugated antibodies (GE Healthcare, Little Chalfont, UK)
and visualizing with Enhanced Chemiluminescence (GE
Healthcare).
BrdU labeling and immuocytochemical analysis
BrdU labeling and immunocytochemistry were per-
formed according to previously reported protocols
[23,27,29]. A549, SBC5 and SW780 cells were incubated
with appropriate media containing 2 μMB r d U( B D
Biosciences, Franklin Lakes, NJ, USA) for 20 min, and
fixed and permeabilized with 100% methanol for 5 min
at room temperature. The cells were washed with PBS,
and then blocked by 3% BSA for 1 h at 37°C. Then, the
cells were incubated with an anti-MCM7 antibody in 3%
BSA overnight at 4°C. After incubation with 1
st anti-
body, the cells were reacted with Alexa Fluor 594-conju-
g a t e dg o a ta n t i - m o u s eI g Gf o r1ha t3 7 ° Ci nt h e
blocking solution. They were then re-fixed, treated with
4 M HCl for 30 min at room temperature and incubated
with FITC-conjugated anti-BrdU (BD Biosciences),
diluted 1:300, for 1 h at room temperature, followed by
observation with confocal microscopy (Leica Microsys-
tems, Wetzlar, Germany).
Immunohistochemical staining and tissue microarray
Immunohistochemical analysis was performed using a
specific mouse-MCM7 antibody as described previously
[27,30]. For clinical lung cancer tissues and liver tissue
microarray (70 cases), ENVISION+ kit/horseradish per-
oxidase (Dako, Glostrup, Denmark) was applied. VEC-
TASTAIN
® ABC KIT (Vector Laboratories, Burlingame,
CA, USA) was used for bladder tissue microarray and
normal tissue slides. Tumor tissue microarrays were
constructed with 331 primary NSCLCs which had been
obtained by a single institutional group (see above) with
an identical protocol to collect, fix, and preserve the tis-
sues after resection [31-33]. Considering the histologic
heterogeneity of individualt u m o r s ,at i s s u ea r e af o r
sampling was selected based on visual alignment with
the corresponding H&E-stained section on a slide.
Three, four or five tissue cores (diameter, 0.6 mm;
depth, 3-4 mm) taken from a donor tumor block were
placed into a recipient paraffin block with a tissue
microarrayer (Beecher Instruments, Sun Prairie, WI,
USA). A core of normal tissue was punched from each
case, and 5-μm sections of the resulting microarray
block were used for immunohistochemical analysis.
Three independent investigators semiquantitatively
assessed MCM7 positivity without prior knowledge of
clinicopathologic data. Because the intensity of staining
within each tumor tissue core was mostly homogeneous,
the intensity of MCM7 staining was semiquantitatively
evaluated using the following criteria: negative (no
appreciable staining in tumor cells) and positive (brown
staining appreciable in more than 30% of the nucleus of
tumor cells). Cases were accepted as positive only if all
reviewers independently defined them as such.
Statistical analysis
The Kruskal-Wallis test was used to examine the differ-
ence between several independent subgroups. Student’s
t-test or Mann-Whitney’s U-test was used to analyze
the difference between two independent subgroups. Sur-
vival curves were calculated from the date of surgery to
the time of death related to NSCLC or to the last fol-
low-up observation. Kaplan-Meier curves were calcu-
lated for each relevant variable and for MCM7
expression; differences in survival times among patient
subgroups were analyzed using the log-rank test. Uni-
variate and multivariate analyses were done with the
Cox proportional hazard regression model to determine
associations between clinicopathological variables and
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between death and possible prognostic factors including
age, gender, histology, pT classification and pN classifi-
cation, taking into consideration one factor at a time.
Second, multivariate Cox analysis was applied on back-
ward (stepwise) procedures that always forced strong
MCM7 expression into the model, along with any and
all variables that satisfied an entry level of P < 0.05. As
the model continued to add factors, independent factors
did not exceed an exit level of P < 0.05.
Results
MCM7 expression is significantly high in lung cancer
tissues and correlated with poor prognosis in NSCLC
We previously reported that PRMT6, a type I arginine
methytransferase, is involved in human carcinogenesis
[27]. To clarify detailed functions of PRMT6 in cancer,
we performed IP-MS analysis and identified MCM7 as a
binding partner (data not shown). The interaction was
confirmed by co-immunoprecipitation and immunocyto-
chemistry (Additional file 3). Intriguingly, quantitative
real-time PCR showed that expression levels of MCM7
in 9 lung cancer tissues (6 NSCLC cases and 3 SCLC
cases) were significantly higher than those in 11 normal
tissues containing lung, brain, colon, esophagus, eye,
liver, rectum, stomach, bladder and kidney (Figure 1A).
Therefore, we hypothesized that MCM7 can also be
involved in human carcinogenesis. To validate these
results, we conducted immunohistochemical analysis on
tissue microarray containing tissue sections from 331
NSCLC patients, who had undergone surgical resection.
Immunohistochemistry using an MCM7-specific anti-
body showed nuclear localization in cancer tissues, but
nothing was detected in normal lung tissues (Figure 1B).
Importantly, specific MCM7 signals were hardly
detected in normal brain, heart, lung, liver, pancreas,
stomach, testis, kidney and bladder tissues (Figure 1C),
indicating that MCM7 may be specifically overexpressed
in cancer tissues. Of 331 cases, MCM7 stained positively
in 196 cases (61.1%) and negatively in 135 cases (38.9%;
Table 1). Subsequently, we analyzed the association of
MCM7 expression with clinical outcomes, and found
that expression of MCM7 in NSCLC patients was signif-
icantly associated with male gender (P < 0.0001, Fisher’s
exact test; Table 1), non-adenocarcinoma (ADC) histol-
ogy (P < 0.0001), presence of lymph node metastasis
(pN1-2; P < 0.0001) and tumor-specific 5-year survival
after the resection of primary tumors (P = 0.0055 by
log-rank test; Figure 1D). We then applied univariate
analysis to evaluate associations between patient prog-
nosis and several factors, including MCM7 expression,
age, gender, histologic type (non-ADC versus ADC), pT
stage (tumor size, T1 versus T2 + T3) and pN stage
(node status, N0 versus N1+N2). All those parameters
were significantly associated with poor prognosis (Table
2). However, multivariate analysis revealed that MCM7
status did not show the statistical significance as an
independent prognostic factor for surgically treated
NSCLC patients enrolled in this study, whereas age, pT
and pN stages did so (Table 2). This result might be
due to the preponderance of MCM7 expression up to
the pN stage.
MCM7 is overexpressed in bladder and various types of
cancers
In addition to lung tissues, we examined expression
levels of MCM7 in bladder tissues. Quantitative real-
time PCR analysis using 23 normal bladder tissues, 124
bladder transitional cell carcinomas (TCCs) and 12
upper urinary tract transitional cell carcinomas (UUT-
TCCs) showed elevated mRNA levels of MCM7 in blad-
der and especially UUT-TCCs compared with normal
bladder tissues (Figure 2A). Although there were signifi-
cant differences between normal bladder and bladder
cancers of all pT stages, no significant differences were
observed between each pT stage nor tumor grade (Fig-
ure 2B; data not shown). Subsequently, immunohisto-
chemical analysis using a bladder tissue microarray
revealed that MCM7 was up-regulated in bladder cancer
tissues at the protein level (21/29, 72.4%; Figure 2C and
Additional file 4). In our microarray expression analysis,
we confirmed elevated MCM7 expression in various
types of cancers including lung, bladder and liver (Table
3), and tissue microarray immunohistochemical analysis
showed up-regulation of MCM7 in liver cancer tissues
at the protein level (25/70, 35.7%; Additional files 5 and
6).
MCM7 is required for cancer cell proliferation
I no r d e rt oe x a m i n ew h e t h e re l e v a t e de x p r e s s i o no f
MCM7 plays a critical role in the proliferation of cancer
cells, we prepared siRNA oligonucleotide duplexes to
specifically suppress the expression of MCM7
(siMCM7#1, #2), and transfected each of them into can-
cer cells. Firstly, we examined the expression profile of
MCM7 in various types of normal and cancer cell lines.
Quantitative real-time PCR and western blot analyses
showed that MCM7 expression levels in cancer cell
lines were significantly higher than those in normal
human cell lines at the RNA and protein levels (Addi-
tional file 7). Knockdown of MCM7 in A549, SBC5 and
SW780 cells was confirmed by western blot and immu-
nocytochemical analyses as shown in Figure 3A. Immu-
nocytochemical analysis showed a decreased proportion
of cells incorporating BrdU after treatment with MCM7
siRNAs and this abrogation of cancer cell growth was
confirmed by the cell viability assay using cell counting
kit 8 (Figure 3A). After confirming that the normal
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growth rate as the cancer cell lines (Additional file 8),
we examined effects of these siRNAs on the normal
cells (Figure 3B). The cell viability analysis revealed that
MCM7 siRNAs had only slight effects on these normal
cell lines relative to cancer cell lines, implying that the
marked suppression of cancer cell growth by treatment
with these specific siRNAs was not dependent on off-
target effects. In addition, we demonstrated the effects
of heliquinomycin, an inhibitor of MCM4/6/7-depen-
dent DNA helicase activity [34], on the growth of cancer
cells. Importantly, it effectively suppressed the growth of
cancer cells compared with HFL-1 cells and this effect
was in a dose dependent manner (Figure 3C). In parti-
cular, after treatment with 4.0 μM of heliquinomycin,
no growth-suppressive effects were observed in HFL-1
cells even though significant growth suppression was
observed in cancer cells. These data indicate that
MCM7 plays an important role in the proliferation of
cancer cells, and inactivation of this gene should be a
promising therapeutic target in various types of cancer.
Discussion
Six of the MCM proteins, MCM2-MCM7, form com-
plexes that participate in initiation and elongation steps
of DNA replication [35]. They share a conserved 200-
amino acid nucleotide-binding region and form different
subcomplexes (dimers, trimers and a hexamer) [36].
MCM4-MCM6-MCM7 trimers and hexamers (MCM2-
MCM7) have ATPase and DNA helicase activities in
vitro [35]. MCM proteins are associated with chromatin
in late telophase and at the beginning of the G1 phase
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Figure 1 Dysregulation of MCM7 in lung cancer tissues, and correlation of MCM7 expression to a negative outcome for NSCLC
patients after surgical operation. (A) Overexpression of MCM7 in clinical lung cancer tissues [NSCLC (n = 6) and SCLC (n = 3)] compared with
several normal tissues (lung, brain, colon, esophagus, eye, heart, liver, rectum, stomach, bladder and kidney) analyzed by quantitative real-time
PCR. Statistical analysis was done using Kruskal-Wallis test; P < 0.0001: Mann Whitney U-test; *, P < 0.05; NS, not significant (P = 0.0528). (B)
Representative cases for positive MCM7 expression in lung ADC, SCC tissues and normal lung tissues. Original magnification, ×100 and ×200. (C)
Immunohistochemical analysis of MCM7 in various normal tissues. No significant staining was observed. Characteristics of each tissue were
described in Additional file 12. (D) Kaplan-Meier estimates of overall survival time of patients with NSCLC (P = 0.0055, log-rank test).
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Page 5 of 11of the cell cycle [37]. During S phase, MCM proteins are
released from origins of replication after initiation of
DNA replication and subsequently move with replica-
tion folks where they are thought to function as a DNA
helicase. Mechanisms that assure the replication of
DNA only once per cycle involve the release of MCM
proteins from chromatin after firing of the origins of
replication and prevent the reloading of MCM proteins
on chromatin until telophase. This evidence indicates
that MCM proteins are one of the essential regulators
in DNA replication, and indeed, it has already been
reported that dysregulation of some MCM proteins is
apparent in human diseases [38-43].
Mukherjee et al recently showed that Rb protein can
bind the MCM complex during late G1 via a direct
interaction with Mcm7, and TGF-b1 blocks their disso-
ciation at G1/S [44]. Overexpression of Mcm7 can speci-
fically and effectively abrogate the ability of TGF-b1t o
acutely block cells in late G1.S i n c et h eR b - b i n d i n gC -
terminal domain of Mcm7 is sufficient for this, Rb and
Mcm7 can form complexes in late G1 that are targeted
by TGF-b1 signals, and perturbation of the Rb-Mcm7
interaction by loss of Rb or overexpression of Mcm7
leads to disruption of TGF-b1’s ability to block late-G1
transit into S phase [44]. These data imply that one rea-
son for the involvement of MCM7 in human cancer we
found may be due to its strong ability to promote cell
cycle progression. Likewise, MCM2, a member of the
family of MCM proteins, was reported as a promising
marker for premalignant lesions of the lung and an
independent predictor of survival in patients with
NSCLC [39,45]. Together with our findings, deregula-
tion of the MCM family protein appears to be closely
linked to human carcinogenesis.
Cancer-related death is on the rise in most countries,
and it is a serious public health problem. It is true that
novel molecular-targeting agents such as cetuximab and
bevacizumab have been developed and proven to be effi-
cacious, but their adverse effects and limited application
Table 1 Association between MCM7-positive in NSCLC
and characteristics of patients
Total MCM7
positive
MCM7
negative
P-value*
positive vs
negative
n=
331
n = 196 n = 135
Gender
Male 236 156 80 <0.0001
Female 95 40 55
Age(years)
<65 168 107 61 NS
≧65 163 89 74
Histological
type
ADC 214 101 113
SCC 78 63 15 <0.0001
†
Others** 39 32 7
pT factor
T1T2 227 127 100 NS
T3T4 104 69 35
pN factor
N0 197 99 98 <0.0001
N1+N2 134 97 37
Abbreviations: ADC, adenocarcinoma; SCC, squamous-cell carcinoma; NS, not
siginificant.
*Fisher’s exact test.
**Others: large-cell carcinoma (LCC) and adenosquamous-cell carcinoma (ASC).
†ADC vs non-ADC.
Table 2 Cox’s proportional hazards model analysis of prognostic factors in patients with NSCLC
Variables Hazards ratio 95%Cl Unfavorable/Favorable P-value*
Univariate analysis
MCM7 1.546 1.134-2.110 Positive/Negative 0.0059
Age (years) 1.354 1.008-1.818 65 ≧/< 65 0.0442
Gender 1.435 1.020-2.020 Female/Male 0.0378
Histological type 1.530 1.138-2.056 nonADC/ADC 0.0048
pT factor 1.647 1.217-2.232 T3T4/T1T2 0.0013
pN factor 2.617 1.945-3.521 N1+N2/N0 <0.0001
Variables Hazards ratio 95%Cl Unfavorable/Favorable P-value*
Multivariate analysis
MCM7 0.935 0.665-1.314 Positive/Negative NS
Age (years) 1.576 1.166-2.130 65 ≧/< 65 0.0031
Gender 0.801 0.553-1.159 Female/Male NS
Histological type 0.819 0.589-1.140 nonADC/ADC NS
pT factor 1.538 1.131-2.092 T3T4/T1T2 0.006
pN factor 2.577 1.887-3.521 N1+N2/N0 <0.0001
Abbreviations: ADC, adenocarcinoma; NS, not siginificant.
*Fisher’s exact test.
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Page 6 of 11for some patients, engender a drive towards novel mole-
cular-targeting agents [46-48]. Recent tumor genomics
data are now assisting in the development of more
rationally selected drugs that target proteins expressed
exclusively or at particularly high levels in tumor com-
pared with essential normal adult cells. It is hoped that
the specific pharmaceutical targeting of such proteins
will result in a new generation of highly active drugs
that are associated with minimal collateral host toxicity
[49]. In this study, we demonstrated that in various can-
cer tissues, expression levels of MCM7 were significantly
high at both mRNA and protein levels whereas those in
various normal tissues were generally low. Although
knockdown of MCM7 expressi o nb ys p e c i f i cs i R N A s
notably suppressed the growth of cancer cells, signifi-
cant growth suppression was hardly observed in the
normal HFL-1 and CCD-18Co cells. Furthermore, an
optimal dose of heliquinomycin, a specific inhibitor of
MCM4/6/7-dependent DNA helicase activity, more
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Figure 2 Elevated MCM7 expression in bladder cancer. (A) mRNA expression levels of MCM7 in 124 bladder transitional cell carcinomas
(TCCs), 12 upper urinary tract transitional cell carcinomas (UUT-TCCs) and 23 normal bladder tissues analyzed by quantitative real-time PCR.
Statistical analysis was done using Kruskal-Wallis test; P < 0.0001: Mann Whitney U-test; **, P < 0.0001. (B) Correlation between MCM7 expression
and pathological tumor stages. Statistical analysis using Kruskal-Wallis test; P < 0.0001: Mann Whitney U-test; **, P < 0.0001. (C)
Immunohistochemical analysis of MCM7 in bladder cancer tissues. Original magnification, ×200.
Table 3 Gene expression profile of MCM7 in cancer
tissues analyzed by cDNA microarray*
Ratio (Tumor/Normal)
Tissue type Case (n) Count > 2
(T/N)
Count > 3
(T/N)
Count > 5
(T/N)
NSCLC 37 9 (24.3%) 4 (10.8%) 0 (0%)
SCLC 15 12 (80.0%) 9 (60.0%) 2 (13.3%)
Esophageal cancer 62 37 (59.7%) 28 (45.2%) 12 (19.4%)
Colorectal cancer 42 17 (40.5%) 9 (21.4%) 0 (0%)
Liver cancer 20 8 (40.0%) 5 (25.0%) 1 (5.0%)
Pancreatic cancer 18 8 (44.4%) 3 (16.7%) 1 (5.6%)
Bladder cancer 34 33 (97.1%) 23 (67.6%) 11 (34.4%)
Testicular cancer 13 10 (76.9%) 7 (53.8%) 4 (30.8%)
AML 56 18 (32.1%) 6 (10.7%) 1 (1.8%)
Osteosarcoma 25 13 (52.0%) 6 (24.0%) 2 (8.0%)
Soft tissue tumor 63 51 (81.0%) 35 (55.6%) 16 (25.4%)
Abbreviations: NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer;
AML, acute myeloid leukemia.
*We compared the signal intensity of MCM7 between tumour tissues and
corresponding non-neoplastic tissues derived from the same patient.
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Page 7 of 11effectively inhibited the growth of cancer cell lines than
that of HFL-1 cell line. These data imply optimized inhi-
bition of MCM7 activity may be a new strategy for can-
cer therapy. Importantly, we found that the growth rate
between human normal and cancer cell lines in culture
(Additional file 8) was not very different, even though
expression levels of MCM7 in cancer cell lines were sig-
nificantly higher than those in normal cell lines, indicat-
ing that overexpressed MCM7 in cancer cells may relate
to some tumor-specific functions, including growth
regulation. This kind of evidence also reinforces the
importance of MCM7 as a target for cancer therapy.
On the contrary, it is known that MCM7 positive cells
are also located in proliferative zone, especially in gas-
trointestinal tract, as well as germinal center cells in
lymph nodes. In this case, we quantitatively compared
MCM7 expression levels in normal gastrointestinal tract
tissues and lung cancer tissues, and the result showed
that expression levels of MCM7 in lung cancer tissues
are significantly higher than those in gastrointestinal
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Figure 3 Involvement of MCM7 in the proliferation of lung and bladder cancer cells. (A) Knockdown effects of siRNAs targeting MCM7 on
cancer cells. Top, western blot analysis of MCM7 in A549, SBC5 and SW780 cells after treatment with two MCM7 siRNAs (siMCM7#1 and
siMCM7#2) and two control siRNAs (siEGFP and siNC). ACTB was used as an internal control. Middle, immunocytochemical analysis of MCM7 in
A549 and SBC5 cells after treatment with siRNAs. The nucleus was stained with DAPI, and the incorporation of 5-bromo-2’-deoxyuridine (BrdU)
into replicating DNA was used to label proliferating cells. Bottom, effects of MCM7 knockdown on the viability of lung and bladder cancer cell
lines (A549, SBC5 and SW780). The viability of cancer cells was measured by Cell Counting Kit-8, and statistical analysis was done using Student’s
t-test. *, P < 0.05. (B) Effects of MCM7 siRNAs on the growth of HFL-1 cells and CCD-18Co cells. The viability of the cells was measured by Cell
Counting Kit-8, and statistical analysis was done using Student’s t-test. NS, not significant. (C) Effects of heliquinomycin on the viability of normal
and cancer cells. Left, the cell vitality assay was performed using Cell Counting Kit-8 after treatment with heliquinomycin for 72 h. Results are the
mean ± SD of three independent experiments. Right, the cell viability of A549, SBC5, SW780 and HFL-1 72 h after treatment with 4.0 μM
heloquinomycin.
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Page 8 of 11tract normal tissues (Additional file 9). The data imply
that expression levels of MCM7 in lung cancer tissues
appear to be significantly higher than those in some
MCM7-expressing normal tissues like gastrointestinal
tissues. Meanwhile, we quantitatively analyzed MCM7
expression levels in 78 normal tissues and found that
MCM7 expression was high in some normal tissues
such as lymphoblasts compared with other normal tis-
sues (Additional file 10). Therefore, we should take this
kind of evidence into consideration when developing
anti-cancer therapy targeting MCM7.
In addition, we clarified the tumor-related arginine
methyltransferase PRMT6 could interact with MCM7 in
t h ep r e s e n ts t u d y .S i n c eb o t ho ft h e s eg e n e sw e r eo v e r -
expressed in tumor tissues, it is possible that these gene
products may cooperatively contribute to human carci-
nogenesis. Although we conducted in vitro methyltrans-
ferase to examine the possibility that MCM7 can serve
as a substrate of PRMT6, we failed to secure the critical
evidence (Additional file 11). With regard to this matter,
we have also been examining the possibility that other
MCM family proteins can interact with PRMT6 and
serve as substrates. Further functional analyses may
make clear the cooperation of PRMT6 in the MCM
complex in human cancer.
Conclusions
Our new findings indicate that MCM7 may be an ideal
target for molecular targeted therapy of cancer without
severe side effects. As anti-cancer drugs targeting DNA
helicases are now in development [50], further validation
of present results may affirm the importance of this pro-
tein as a promising target for anti-cancer therapy.
Furthermore, among all types of cancer, lung cancer is
the leading cause of death from cancer in the United
States and Japan, and the median survival of advanced
NSCLC patients treated with standard chemotherapy
still remains as short as about 8 months [51,52]. MCM7
could therefore be a good indicator enabling us to pre-
dict prognosis of NSCLC patients and to conduct a
more intensive follow-up according to MCM7 expres-
sion status of resected specimens.
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Additional file 1: Primer sequences for quantitative RT-PCR. Specific
primer sequence for GAPDH (housekeeping gene) and MCM7,
respectively.
Additional file 2: siRNA sequences. Sequences of siEGFP, siNC
(Negative Control) and siMCM7, respectively.
Additional file 3: PRMT6 associates with MCM7. (A) FLAG-mock or
FLAG-PRMT6 expression vectors were co-transfected with HA-Mock or
HA-MCM7 expression vectors into 293T cells. After 48 h, cells were
immunoprecipitated with anti-FLAG M2 agarose (SIGMA) or -HA agarose
(SIGMA), and immunoprecipitants were immunoblotted with anti-FLAG
and -HA antibodies, respectively. (B) FLAG-PRMT6 could interact with
endogenous MCM7 proteins. FLAG-Mock or FLAG-PRMT6 expression
vectors were transfected into 293T cells. After 48 h, cells were
immunoprecipitated with anti-FLAG M2 agarose, and
immunoprecipitants were immunoblotted with anti-MCM7 and -FLAG
antibodies, respectively. (C) PRMT6 and MCM7 were co-localized in the
nucleus. HeLa cells were stained with anti-FLAG antibody (Alexa Fluor
®®
488 [green]), anti-HA antibody (Alexa Fluor
®® 594 [red]) and 4’,6’-
diamidine-2’-phenylindole dihydrochloride (DAPI [blue]).
Additional file 4: Clinicopathological characteristics of bladder
tissues on the tissue microarray. Clinicopathological information of
bladder tumor tissues and MCM7 expression levels at the protein level.
Additional file 5: Immunohistochemical analysis of MCM7 in liver
cancer tissues. Original magnification, ×200.
Additional file 6: Clinicopathological characteristics of liver tissues
on the tissue microarray. Clinicopathological information of liver tumor
tissues and MCM7 expression levels at the protein level.
Additional file 7: Expression levels of MCM7 in various types of
cancer cell lines. (A) mRNA expression levels of MCM7 in 5 normal
human cell lines, 15 lung cancer cell lines, 3 bladder-cancer cell lines, 3
liver cancer cell lines, and 3 colorectal cancer cell lines examined by
quantitative real-time PCR. (B) Protein expression levels of MCM7 in HFL-
1, A549, SBC5 and SW780 cell lines examined by western blot. ACTB
serves as a loading control.
Additional file 8: The growth rate of various types of cell lines. Cell
growth was calculated using Cell Counting Kit-8 and cell number shows
the relative value compared to that at 0 h (cell number at 0 h = 1). The
experiment was performed during the logarithmic growth phase.
Additional file 9: Expression levels of MCM7 in gastrointestinal tract
(GIT) normal tissues (colon, esophagus, rectum and stomach) and
lung cancer tissues. (A) mRNA expression levels of MCM7 in GIT normal
tissues and lung cancer tissues examined by quantitative real-time PCR.
(B) Comparison of MCM7 expression between GIT normal tissues and
lung cancer tissues based on the real-time PCR result shown in (A).
Mann-Whitney’s U-test was used for statistical analysis, and data are
shown by box-whisker plot (median 50% boxed).
Additional file 10: Expression levels of MCM7 in 78 normal tissues.
The data were derived from BioGPS http://biogps.gnf.org/
#goto=welcome. GAPDH expression is shown as a control for signal
intensity.
Additional file 11: MCM7 was not methylated by PRMT6. For the in
vitro methyltransferase assay, recombinant MCM7 proteins were
incubated with active PRMT6 using 2 μCi S-adenosyl-L-[methyl-
3H]
methionine (SAM; Amersham Biosciences) as the methyl donor in a
mixture of 10 μl of methylase activity buffer (50 mM Tris-HCl at pH8.5, 10
mM DTT and 10 mM MgCl2), for 1 h at 30°C. Proteins were resolved on a
5-20% SDS-PAGE gel (Ready Gel; Bio-Rad, Hercules, CA, USA) and
visualized by fluorographyand ponceau S staining.
Additional file 12: Characteristics of various normal tissues. Clinical
information of normal organs.
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